相关实验视频
Updated: May 28, 2025

04:34
Mouse Complete Stasis Model of Inferior Vena Cava Thrombosis
Published on: June 15, 2011
18.2K
lysophosphatidic 酸 2 通过保护性内皮屏障功能减轻深静脉血栓形成
Ruifeng Bai1, Xinyang Yue2, Xuan Tian3
1Department of Clinical Laboratory, Beijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China.
Open medicine (Warsaw, Poland)
|February 10, 2025
概括
Lysophosphatidic 酸 2 (LPA2) 通过保持内皮屏障完整性,可以防止深静脉血栓症 (DVT). 缺乏LPA2会加剧DVT的进展和血栓炎症,突出其保护作用.
科学领域:
- 心血管研究研究心血管研究
- 血栓形成和血液静止.
- 分子医学是分子医学.
背景情况:
- lysophosphatidic acid 2 (LPA2) 在深静脉血栓形成 (DVT) 的精确功能尚不清楚.
- 研究LPA2的作用对于理解DVT机制和开发向疗法至关重要.
研究的目的:
- 阐明LPA2在深静脉血栓症 (DVT) 的发展和进展中的特定作用.
- 确定LPA2对内皮屏障功能和DVT期间炎症的影响.
主要方法:
- 在野生类型和LPA2淘汰赛小鼠中建立了DVT的下静脉环收缩模型.
- 评估了DVT发生率,血栓特征和内皮透气性 (体内和体外).
- 利用蛋白质组学,组织病理学,免疫组织化学和西方涂抹来研究分子机制.
主要成果:
- 缺乏LPA2显著增加了血管内皮透气性,并促进了DVT的进展.
- 组织学分析显示,LPA2淘汰赛小鼠中瘤的炎症加重.
- 蛋白质组分析表明,LPA2缺乏,DVT和紧结 (TJ) 蛋白质的改变之间存在联系. 治疗LPA2激动剂恢复了内皮屏障功能,并增加了zonula occludens-1的表达.
结论:
- 在DVT期间,LPA2在保护内皮屏障功能方面发挥着至关重要的作用.
- 这些发现揭示了一种新的机制,即LPA2通过维持内皮质完整性来减轻DVT的进展.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
601
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
601
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
461
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
461
Vascular Spasm
1.2K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
1.2K
Clot Retraction and Fibrinolysis
3.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
145
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
145
Phosphoinositides and PIPs
8.3K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.3K

